A rising multiple-dose study gave 40 healthy volunteers trans-resveratrol 25 to 150 mg six times daily for 13 doses, or placebo. Peak plasma concentrations remained low relative to the doses given (mean peak concentration 3.89 to 63.8 ng/mL across the dose range) with interindividual variability exceeding 40%, and half-life was 1 to 3 hours after a single dose and 2 to 5 hours after repeated dosing. Tolerability over this brief, company-sponsored exposure does not establish longevity benefit or long-term safety.[1]
- Short formulation-specific pharmacokinetic study sponsored by a company with resveratrol-related staff among the authors; no longevity or disease-prevention outcomes were measured.
- Abstract-checked; no qualified clinical review.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.
· Reopened the PubMed structured abstract via E-utilities and added exact Cmax/half-life ranges by dose and the sponsor's staff affiliations. No PMC full text available. Independent editorial review pending; no qualified clinical review.